Nexodal (Naloxone Hydrochloride)

Naloxone is a competitive antagonist at the μ‑opioid receptor. By binding to these receptors without activating them, it displaces opioid agonists, thereby terminating their depressant effects on the central nervous system, especially the brainstem respiratory centers, and restoring normal breathing.

The specific dose of Nexodal is determined by the prescribing clinician based on the patient’s condition, the route of administration (intramuscular or intravenous), and the severity of opioid toxicity. Standard emergency protocols often start with 0.4 mg to 2 mg, but exact dosing must follow local guidelines.

Safety data for naloxone during pregnancy and lactation are limited. Because naloxone does not cross the placenta in significant amounts and is not excreted in breast milk at clinically relevant levels, it is generally considered low risk, but use should be limited to situations where the benefit outweighs any potential risk and under medical supervision.

To place an order, submit an enquiry on the Nexodal product page at gnhindia.com, specifying the required quantity and providing institutional or trade credentials. GNH India’s sales team will verify eligibility, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation for hospitals, pharmacies or procurement agencies worldwide.

Nexodal contains naloxone, the most widely used opioid antagonist for acute reversal. Compared with alternatives such as nalmefene or naltrexone, naloxone has a rapid onset of action (1–2 minutes intravenously) and a relatively short half‑life, making it ideal for emergency settings where quick reversal is needed, whereas the others are longer‑acting and used for maintenance therapy.

Nexodal should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the vial from direct sunlight, moisture and extreme temperatures. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration and discard if any abnormalities are observed.

Nexodal is supplied as a sterile injection solution for intramuscular or intravenous use. Administration is performed by a qualified healthcare professional using aseptic technique. For intramuscular injection, the dose is delivered into a large muscle (e.g., thigh or deltoid). For intravenous use, the solution is injected slowly into a peripheral vein, with continuous monitoring of the patient’s respiratory and cardiovascular status.

The most serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, and anaphylactic reactions, which may occur rarely but require immediate medical intervention. Additionally, rapid reversal of opioid effects can precipitate acute withdrawal symptoms, especially in patients with opioid dependence, leading to agitation, vomiting, or tachycardia.

Nexodal is contraindicated in individuals with a known hypersensitivity to naloxone or any component of the formulation. It should also be used with caution in patients with pre‑existing cardiovascular disease, uncontrolled hypertension, or those receiving mixed agonist‑antagonist opioids, as abrupt reversal may exacerbate underlying conditions.